MX376186B - Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio. - Google Patents

Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio.

Info

Publication number
MX376186B
MX376186B MX2016006066A MX2016006066A MX376186B MX 376186 B MX376186 B MX 376186B MX 2016006066 A MX2016006066 A MX 2016006066A MX 2016006066 A MX2016006066 A MX 2016006066A MX 376186 B MX376186 B MX 376186B
Authority
MX
Mexico
Prior art keywords
pyrrolo
virus infections
syncytum
treating respiratory
triazines useful
Prior art date
Application number
MX2016006066A
Other languages
English (en)
Other versions
MX2016006066A (es
Inventor
Dustin Siegel
Edward Doerffler
Hanrahan CLARKE Michael O'neil
Richard L Mackman
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376186(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2016006066A publication Critical patent/MX2016006066A/es
Publication of MX376186B publication Critical patent/MX376186B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente solicitud se proveen formulaciones, métodos y compuestos de tetrahidrofuranil-pirrolo[1,2-f][1,2,4]triazin-4-amina sustituidos de la Fórmula (I) para tratar infecciones por virus Pneumovirinae, incluyendo infecciones por virus del sincitio repiratorio, así como métodos e intermediarios para la síntesis de compuestos de tetrahidrofuranil-pirrolo[1,2-f][1,2,4]triazin-4-amina.
MX2016006066A 2013-11-11 2014-11-06 Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio. MX376186B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
PCT/US2014/064412 WO2015069939A1 (en) 2013-11-11 2014-11-06 Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

Publications (2)

Publication Number Publication Date
MX2016006066A MX2016006066A (es) 2016-08-12
MX376186B true MX376186B (es) 2025-03-07

Family

ID=52003049

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006066A MX376186B (es) 2013-11-11 2014-11-06 Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio.
MX2020010628A MX2020010628A (es) 2013-11-11 2016-05-09 Pirrolo[1,2-f][1,2,4]triazinas utiles para tratar infecciones por virus del sincitio respiratorio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010628A MX2020010628A (es) 2013-11-11 2016-05-09 Pirrolo[1,2-f][1,2,4]triazinas utiles para tratar infecciones por virus del sincitio respiratorio.

Country Status (36)

Country Link
US (5) US9388208B2 (es)
EP (3) EP3505173B1 (es)
JP (7) JP6234571B2 (es)
KR (4) KR101864973B1 (es)
CN (3) CN105899216B (es)
AP (1) AP2016009186A0 (es)
AU (5) AU2014346665A1 (es)
BR (1) BR112016010261B1 (es)
CA (1) CA2928674C (es)
CL (1) CL2016001120A1 (es)
CR (1) CR20160220A (es)
CU (1) CU20160065A7 (es)
CY (1) CY1121948T1 (es)
DK (2) DK3068405T3 (es)
DO (1) DOP2016000107A (es)
EA (2) EA029712B1 (es)
ES (2) ES2743619T3 (es)
GT (1) GT201600086A (es)
HR (2) HRP20220920T1 (es)
HU (2) HUE044960T2 (es)
IL (1) IL245324B (es)
LT (2) LT3068405T (es)
MD (1) MD4596C1 (es)
MX (2) MX376186B (es)
MY (2) MY182986A (es)
NZ (1) NZ719592A (es)
PE (1) PE20160670A1 (es)
PH (1) PH12016500867A1 (es)
PL (2) PL3068405T3 (es)
PT (2) PT3068405T (es)
SG (1) SG11201603427XA (es)
SI (2) SI3068405T1 (es)
TR (1) TR201910961T4 (es)
UA (1) UA119050C2 (es)
WO (1) WO2015069939A1 (es)
ZA (1) ZA201603123B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012006180A2 (pt) 2009-09-21 2015-09-08 Gilead Sciences Inc processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
AU2015320511B2 (en) 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
TWI687432B (zh) * 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
BR122020020217B1 (pt) 2015-09-16 2021-08-17 Gilead Sciences, Inc Uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por arenaviridae
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
EP3426642A4 (en) 2016-03-09 2019-10-09 Janssen BioPharma, Inc. ACYCLIC VIRUIDE
EP4331677A3 (en) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
PL3651734T3 (pl) 2017-07-11 2025-03-31 Gilead Sciences, Inc. Kompozycje zawierające inhibitor polimerazy rna i cyklodekstrynę do leczenia infekcji wirusowych
US11149049B2 (en) * 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN115135383B (zh) 2020-02-18 2024-06-11 吉利德科学公司 抗病毒化合物
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) * 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
TW202532084A (zh) 2020-05-29 2025-08-16 美商基利科學股份有限公司 瑞德西韋之治療方法
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
EP4192839B1 (en) 2020-08-06 2025-10-01 Richter Gedeon Nyrt. Remdesivir intermediates
CN116323630A (zh) 2020-08-24 2023-06-23 吉利德科学公司 磷脂化合物及其用途
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
TWI811812B (zh) * 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
CA3229752A1 (en) 2021-08-20 2023-02-23 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
JP2025508942A (ja) 2022-03-02 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
EP4486747A1 (en) * 2022-03-03 2025-01-08 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
KR20240155326A (ko) 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
TW202517647A (zh) 2023-09-28 2025-05-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
PL2114980T3 (pl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Przeciwwirusowe analogi nukleozydów
AU2008251555B2 (en) 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
ATE515861T1 (de) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy Verfahren zur adressierung von ethernetströmen mit strukturierter gpon-gem-port-id
CN102015714B (zh) * 2008-04-23 2014-09-24 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
BR112012006180A2 (pt) 2009-09-21 2015-09-08 Gilead Sciences Inc processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
SMT201700091T1 (it) * 2009-09-21 2017-03-08 Gilead Sciences Inc ANALOGHI CARBA-NUCLEOSIDlCI2'-FLUORO SOSTITUITI PER TRATTAMENTO ANTIVIRALE
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
PT2596004E (pt) 2010-07-19 2014-11-28 Gilead Sciences Inc Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros
SG186830A1 (en) * 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
PH12013500311B1 (en) * 2010-09-20 2017-11-08 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2011349844B2 (en) * 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
SMT201800662T1 (it) * 2011-12-22 2019-01-11 Alios Biopharma Inc Nucleotidi, nucleosidi sostituiti e loro analoghi
JP6242378B2 (ja) * 2012-03-13 2017-12-06 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
ES2743619T3 (es) 2020-02-20
JP7054394B2 (ja) 2022-04-13
ES2926155T3 (es) 2022-10-24
MY182986A (en) 2021-02-05
AP2016009186A0 (en) 2016-04-30
MY197933A (en) 2023-07-25
IL245324B (en) 2018-08-30
EA039734B1 (ru) 2022-03-04
AU2023202506B2 (en) 2025-01-23
EA029712B1 (ru) 2018-05-31
CR20160220A (es) 2016-07-22
NZ719592A (en) 2017-12-22
TR201910961T4 (tr) 2019-08-21
SI3068405T1 (sl) 2019-08-30
AU2019204381B2 (en) 2021-04-01
EA201690978A1 (ru) 2016-09-30
JP2021046413A (ja) 2021-03-25
JP2018070658A (ja) 2018-05-10
US20250236623A1 (en) 2025-07-24
AU2017232039B2 (en) 2019-03-28
HUE059683T2 (hu) 2022-12-28
JP2017502925A (ja) 2017-01-26
AU2021201554A1 (en) 2021-04-01
AU2017232039A1 (en) 2017-10-12
BR112016010261A2 (es) 2017-08-08
AU2023202506A1 (en) 2023-05-11
CN105899216A (zh) 2016-08-24
CY1121948T1 (el) 2020-10-14
JP2018021051A (ja) 2018-02-08
HRP20220920T1 (hr) 2022-10-28
PH12016500867A1 (en) 2016-06-20
PT3505173T (pt) 2022-11-18
SG11201603427XA (en) 2016-05-30
CN114085243B (zh) 2024-04-26
PT3068405T (pt) 2019-08-05
KR102243724B1 (ko) 2021-04-23
HUE044960T2 (hu) 2019-12-30
IL245324A0 (en) 2016-06-30
AU2019204381A1 (en) 2019-07-11
AU2021201554B2 (en) 2023-02-02
BR112016010261B1 (pt) 2022-02-08
US9701682B2 (en) 2017-07-11
CN110003215A (zh) 2019-07-12
DK3505173T3 (da) 2022-08-22
US10377761B2 (en) 2019-08-13
JP2022088661A (ja) 2022-06-14
AU2017232039C1 (en) 2019-07-25
KR101864973B1 (ko) 2018-06-05
SI3505173T1 (sl) 2022-09-30
LT3505173T (lt) 2022-10-10
PE20160670A1 (es) 2016-07-10
US20190055253A1 (en) 2019-02-21
US20170008897A1 (en) 2017-01-12
KR20200057103A (ko) 2020-05-25
MD4596C1 (ro) 2019-05-31
MX2016006066A (es) 2016-08-12
JP6393380B2 (ja) 2018-09-19
LT3068405T (lt) 2019-08-12
AU2014346665A1 (en) 2016-05-19
KR20180059958A (ko) 2018-06-05
KR102113705B1 (ko) 2020-05-21
EP3505173A1 (en) 2019-07-03
CU20160065A7 (es) 2016-09-30
CA2928674A1 (en) 2015-05-14
UA119050C2 (uk) 2019-04-25
CL2016001120A1 (es) 2017-05-05
KR102355881B1 (ko) 2022-01-25
CA2928674C (en) 2018-10-02
EP3068405A1 (en) 2016-09-21
DK3068405T3 (da) 2019-07-29
MX2020010628A (es) 2020-10-22
KR20210046833A (ko) 2021-04-28
PL3505173T3 (pl) 2022-10-17
US20150133395A1 (en) 2015-05-14
JP7247155B2 (ja) 2023-03-28
MD20160063A2 (ro) 2016-11-30
EP3505173B1 (en) 2022-07-06
EA201792639A1 (ru) 2018-09-28
WO2015069939A1 (en) 2015-05-14
CN105899216B (zh) 2019-03-05
JP6234571B2 (ja) 2017-11-22
HRP20191303T1 (hr) 2019-10-18
GT201600086A (es) 2018-01-17
DOP2016000107A (es) 2016-06-15
JP2024041986A (ja) 2024-03-27
KR20160074011A (ko) 2016-06-27
PL3068405T3 (pl) 2019-10-31
CN114085243A (zh) 2022-02-25
ZA201603123B (en) 2019-08-28
EP4122932A1 (en) 2023-01-25
CN110003215B (zh) 2021-12-17
JP2020055855A (ja) 2020-04-09
US9388208B2 (en) 2016-07-12
US20180016280A1 (en) 2018-01-18
US10059716B2 (en) 2018-08-28
EP3068405B1 (en) 2019-05-01
MD4596B1 (ro) 2018-10-31

Similar Documents

Publication Publication Date Title
MX376186B (es) Pirrolo [1,2-f] [1,2,4] triazinas utiles para tratar infecciones por virus del sincitio respiratorio.
NZ728707A (en) 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
CL2013000077A1 (es) Uso de compuestos derivados de ribosas 1’ sustituidas que comprenden nucleobases de pirrolo[1,2-f][1,2,4]triazina para tratar infecciones por paramyxoviridae; compuestos derivados de ribosas 1’ sustituidas que comprenden nucleobases de pirrolo[1,2-f][1,2,4]triazina; y composicion farmaceutica que los comprende.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CO6852080A2 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincital repiratorio
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
EA201792370A1 (ru) Пиразоло- и триазолопиримидиновые соединения с противовирусной активностью по отношению к rsv
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
TW201129572A (en) Compounds for treating respiratory syncytial virus infections
EA201590656A1 (ru) Азаиндолины
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA201690400A1 (ru) Замещенные имидазолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX391523B (es) Intermediarios y metodos para sintetizar derivados de calicheamicina
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
NZ758580A (en) Pyrrolo[2,1-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.

Legal Events

Date Code Title Description
FG Grant or registration